Exclusive-US FDA delays two drug reviews in new voucher program after safety, efficacy concerns
Jan 15 (Reuters) – The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for…
Why Disc Medicine (IRON) Is Up 28.7% After Securing FDA Priority Review for Bitopertin Accelerated Approval
Disc Medicine announced it received a Commissioner’s National Priority Voucher from the US FDA for bitopertin in erythropoietic…